News
Investigation next-generation antibiotics continues with ERC grant Nathaniel Martin
Nathaniel Martin has received the Proof of Concept (PoC) grant. The European Research Council (ERC) awarded Martin this grant to continue his research on reducing the toxicity of the antibiotic polymyxin: A potent medicine, but with severe side effects. He receives €150.000.
Gilles van Wezel receives ERC Advanced grant to awaken sleeping antibiotics
The ERC Advanced grant is awarded to Gilles van Wezel, Professor of Molecular Biotechnology of the Institute Biology Leiden (IBL) of Leiden University. With the 2.5 million euro grant of the European Research Council, he will focus on unravelling the systems that control the production of antibiotics in the bacteria Streptomyces.
First investments of AMR Action Fund
The AMR Action Fund has announced its first investment to fulfill its aim to bring two to four new antibiotics to market. The fund will provide for research in Adaptive Phagte Therapeutics (APT) and Venatorx Pharmaceuticals.
2021 Antimicrobial Resistance Benchmark report
The third AMR Benchmark is an independent report that compares and analyses how pharmaceutical companies are responding to the crisis of antimicrobial resistance.
Join the next GARDP AMR discussion 19th November
This World Antimicrobial awareness week, GARDP, together with WHO, will be holding an AMR Discussions webinar. A panel will discuss the roles that different actors can play in the development of new antibiotics.
Media-attention for AMR: “Create anti-bodies to strengthen bodies’ defences.”
For the Dutch radio program at NPO radio 1, Suzan Rooijakkers, explains how Antimicrobial Resistance (AMR) continues to threaten our abilities to treat common infections.